17-Jul-2026
No headlines found.
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
Globe Newswire (Tue, 14-Jul 5:43 PM ET)
LeMaitre to Participate at Upcoming Investor Conferences in June
Globe Newswire (Wed, 20-May 4:25 PM ET)
LeMaitre to Present at the Bank of America Healthcare Conference
Globe Newswire (Thu, 7-May 5:15 PM ET)
LeMaitre Q1 2026 Financial Results
Globe Newswire (Tue, 5-May 4:05 PM ET)
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Lemaitre Vascular trades on the NASDAQ stock market under the symbol LMAT.
As of July 17, 2026, LMAT stock price declined to $101.63 with 260,211 million shares trading.
LMAT has a beta of 0.42, meaning it tends to be less sensitive to market movements. LMAT has a correlation of 0.02 to the broad based SPY ETF.
LMAT has a market cap of $2.32 billion. This is considered a Mid Cap stock.
Last quarter Lemaitre Vascular reported $67 million in Revenue and $.68 earnings per share. This fell short of revenue expectation by $-119,480 and exceeded earnings estimates by $.02.
In the last 3 years, LMAT traded as high as $118.01 and as low as $44.27.
The top ETF exchange traded funds that LMAT belongs to (by Net Assets): IJR, SDVY, VTI, IWM, VXF.
LMAT has outperformed the market in the last year with a return of +24.9%, while the SPY ETF gained +19.5%. However, in the most recent history, LMAT shares have underperformed the stock market with its stock returning -10.9% in the last 3 month period and -1.2% for the last 2 week period, while SPY has returned +4.9% and -0.2%, respectively.
LMAT support price is $100.58 and resistance is $105.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LMAT shares will trade within this expected range on the day.